Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals Limited has submitted to NSE the newspaper cuttings (published in The Economic Times in English and Navgujarat Samay in Gujarati on May 9, 2025) of its audited standalone financial results for Q4 and full year FY25. For Q4 FY25, total income from operations was Rs. 2,232.99 lakhs and net profit after tax was Rs. 165.10 lakhs, compared to Rs. 371.94 lakhs in Q4 FY24 — a sharp year-on-year decline of roughly 56%. For the full year FY25, total income rose to Rs. 10,097.35 lakhs (from Rs. 9,564.04 lakhs in FY24, up about 5.6%), but net profit after tax slipped to Rs. 1,335.79 lakhs from Rs. 1,450.10 lakhs in FY24, a drop of nearly 8%. The filing is a routine regulatory disclosure under SEBI Listing Regulation 47 and contains no new business announcement beyond the already-published results.
This is purely a compliance submission of newspaper clippings, so there is no fresh catalyst for the stock. However, the underlying numbers show weak Q4 profitability (net profit down ~56% YoY) and a slight dip in full-year profit despite revenue growth, which investors may view negatively when assessing earnings quality.